Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

SIMPLE SUMMARY: Patients with platinum-resistant ovarian cancer experience poor prognosis. No mature evidence supports the routine adoption of immunotherapy alone in this setting. However, the combination of immunotherapy with target therapies seems to be a promising option in patients with ovarian...

Descripción completa

Detalles Bibliográficos
Autores principales: Indini, Alice, Nigro, Olga, Lengyel, Csongor György, Ghidini, Michele, Petrillo, Angelica, Lopez, Salvatore, Raspagliesi, Francesco, Trapani, Dario, Khakoo, Shelize, Bogani, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037571/
https://www.ncbi.nlm.nih.gov/pubmed/33916221
http://dx.doi.org/10.3390/cancers13071663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037571/
https://www.ncbi.nlm.nih.gov/pubmed/33916221
http://dx.doi.org/10.3390/cancers13071663

Ejemplares similares